Please use a PC Browser to access Register-Tadawul
Get It
NAYA Biosciences Announces Development Of NY-500 Novel AI-Optimized PD-1 X VEGF Bifunctional Antibody
NAYA Biosciences, Inc. - Common Stock NAYA | 0.36 | 0.00% |
PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications
• NAYA aiming to initiate clinical trials in early 2026